Recent released report, title "Personalized Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025"
Albany, NY -- (SBWIRE) -- 04/16/2018 -- Personalized therapy is related to the genetic makeup of a person. It helps doctors to understand how a tumor grows in a particular patient to identify effective screening, control, and treatment methods. : Doctors are engaged in developing novel treatments with fewer side effects as compared to the traditional treatments. Doctors perform various genetic tests on cancer cells and on normal cells, to develop new customized treatment according to the patient's needs.
Before personalized therapy, most patients with a specific stage and type of cancer received similar treatment. However, it is evident that certain treatments work specifically on some patients and give better results, as compare to other patients. Development in the field of genetics has led scientists to identify genetic differences in certain patients and their cancer, this described several other responses to treatment. A cancer patient can obtain a standard treatment strategy, such as tumor removal. The doctors can prescribed a personalized cancer treatment. Personalized therapy is an important part of cancer treatment or a part of the clinical trial. A clinical trial is an investigation study including people.
Get the sample copy of report @ https://www.marketresearchreports.biz/sample/sample/1430796
Targeted cancer treatment targets specific genes and proteins that allow cancer cells to survive and grow. Research scientists are continuously identifying new targets each year. They develop and test new medicines for these new targets. Targeted therapy is used for lung cancer, kidney cancer, gastrointestinal stromal tumor, colorectal cancer, and breast cancer, among others. For the treatment of cancer by targeted therapy, it is very important to find out whether the tumor has specific target or not, and this can be identify by the testing of the tumor sample.
Therapy that targets definite mutant genes, have been existing for few type of cancers since 2001, and by the several studies researchers determined that which tumors will respond best with which drug. For example, changes in the epidermal growth factor receptor (EGFR) gene that affects the response of patient, suffering with lung cancer when the medicine target the EGFR protein. However, recent studies have indicated the shortcomings of targeted therapy by highlighting that the genetic origins of several cancers are both complex and unclear. An extensive diversity of rare mutations can give rise to any type of cancer and mutations in the similar genetic pathways arise in several types of tumors. Rise in the prevalence of cancer, across the world, growing awareness about existing treatments available in the market, and an increasing directness toward the acceptance of promising innovative treatment procedures are key factor driving the global personalized cancer therapy market. The market is also driven by substantial developments in gene sequencing methods and high accuracy in its results.
The global personalized cancer therapy market has been segmented into application, technique, technology, and geography. In terms of technique, the global personalized cancer therapy market has been classified into genomics, proteomics, epigenetics, and metabolomics. Based on technology, the market has been segmented into immunohistochemistry, in situ hybridization (ISH), quantitative PCR, next-generation sequencing, and microarray. In terms of application the global personalized cancer therapy market has been categorized into personalized medicines, biomarker discoveries, diagnostics, prognostics, and research applications. Based on geography, the global personalized cancer therapy market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Request for more information on this market @ https://www.marketresearchreports.biz/sample/enquiry/1430796
Key players operating in the global personalized cancer therapy market include Illumina Inc., QIAGEN N.V., NeoGenomics Laboratories, HTG Molecular Diagnostic, and Genomic Health Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry's value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR's reports, recent market/vendor-specific changes may take time to reflect in the analysis.